The coordinated action of VCP/p97 and GCN2 regulates cancer cell metabolism and proteostasis during nutrient limitation.


Journal

Oncogene
ISSN: 1476-5594
Titre abrégé: Oncogene
Pays: England
ID NLM: 8711562

Informations de publication

Date de publication:
04 2019
Historique:
received: 08 05 2018
accepted: 07 12 2018
revised: 05 12 2018
pubmed: 11 1 2019
medline: 22 5 2019
entrez: 11 1 2019
Statut: ppublish

Résumé

VCP/p97 regulates numerous cellular functions by mediating protein degradation through its segregase activity. Its key role in governing protein homoeostasis has made VCP/p97 an appealing anticancer drug target. Here, we provide evidence that VCP/p97 acts as a regulator of cellular metabolism. We found that VCP/p97 was tied to multiple metabolic processes on the gene expression level in a diverse range of cancer cell lines and in patient-derived multiple myeloma cells. Cellular VCP/p97 dependency to maintain proteostasis was increased under conditions of glucose and glutamine limitation in a range of cancer cell lines from different tissues. Moreover, glutamine depletion led to increased VCP/p97 expression, whereas VCP/p97 inhibition perturbed metabolic processes and intracellular amino acid turnover. GCN2, an amino acid-sensing kinase, attenuated stress signalling and cell death triggered by VCP/p97 inhibition and nutrient shortages and modulated ERK activation, autophagy, and glycolytic metabolite turnover. Together, our data point to an interconnected role of VCP/p97 and GCN2 in maintaining cancer cell metabolic and protein homoeostasis.

Identifiants

pubmed: 30626938
doi: 10.1038/s41388-018-0651-z
pii: 10.1038/s41388-018-0651-z
pmc: PMC6756015
doi:

Substances chimiques

Nuclear Proteins 0
Glutamine 0RH81L854J
EIF2AK4 protein, human EC 2.7.11.1
Protein Serine-Threonine Kinases EC 2.7.11.1
Adenosine Triphosphatases EC 3.6.1.-
p97 ATPase EC 3.6.1.-
VCP protein, human EC 3.6.4.6
Valosin Containing Protein EC 3.6.4.6
Glucose IY9XDZ35W2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3216-3231

Subventions

Organisme : Cancer Research UK
ID : 12011
Pays : United Kingdom
Organisme : Cancer Research UK (CRUK)
ID : C41494/A15448
Pays : International
Organisme : Cancer Research UK (CRUK)
ID : A22544
Pays : International

Références

Mol Cell. 2000 Nov;6(5):1099-108
pubmed: 11106749
Nature. 2001 Dec 6;414(6864):652-6
pubmed: 11740563
Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):190-5
pubmed: 11756670
Nature. 2002 Jul 25;418(6896):387-91
pubmed: 12140549
Mol Cell Biol. 2002 Oct;22(19):6681-8
pubmed: 12215525
J Clin Oncol. 2003 Feb 1;21(3):447-52
pubmed: 12560433
J Clin Oncol. 2003 Jul 1;21(13):2537-44
pubmed: 12829673
J Cell Biol. 2003 Jul 7;162(1):71-84
pubmed: 12847084
Science. 1956 Jul 20;124(3212):124-5
pubmed: 13337363
Nature. 1959 Apr 25;183(4669):1201-2
pubmed: 13657053
Cell. 2003 Oct 31;115(3):355-67
pubmed: 14636562
Clin Cancer Res. 2004 May 1;10(9):3007-12
pubmed: 15131036
J Biol Chem. 2004 Aug 27;279(35):36553-61
pubmed: 15213227
Proc Natl Acad Sci U S A. 2005 Oct 4;102(40):14132-8
pubmed: 16186510
Science. 2005 Dec 23;310(5756):1960-3
pubmed: 16373576
Cell. 2006 Jul 28;126(2):361-73
pubmed: 16873066
Dev Cell. 2006 Dec;11(6):803-16
pubmed: 17141156
Biochem Biophys Res Commun. 2007 Mar 9;354(2):459-65
pubmed: 17239345
Nat Cell Biol. 2007 Apr;9(4):379-90
pubmed: 17369820
J Biol Chem. 2008 Oct 31;283(44):30289-99
pubmed: 18715868
Nat Methods. 2009 Apr;6(4):275-7
pubmed: 19305406
Cancer Res. 2009 Jun 1;69(11):4918-25
pubmed: 19458066
J Biol Chem. 2009 Nov 20;284(47):32742-9
pubmed: 19783659
J Gen Physiol. 1927 Mar 7;8(6):519-30
pubmed: 19872213
Anal Chem. 2009 Dec 15;81(24):10038-48
pubmed: 19928838
Autophagy. 2010 Feb;6(2):217-27
pubmed: 20104022
Clin Cancer Res. 2010 Mar 15;16(6):1856-64
pubmed: 20215539
EMBO J. 2010 Jun 16;29(12):2082-96
pubmed: 20473272
Trends Biochem Sci. 2010 Aug;35(8):427-33
pubmed: 20570523
Mol Biol Cell. 2010 Sep 15;21(18):3220-31
pubmed: 20660158
Mol Cell. 2010 Oct 8;40(1):147-58
pubmed: 20932482
Mol Cell. 2011 Jan 7;41(1):82-92
pubmed: 21211725
Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):4834-9
pubmed: 21383145
EMBO J. 1990 Jun;9(6):1757-67
pubmed: 2140770
Anal Biochem. 2011 Aug 15;415(2):206-8
pubmed: 21575589
Nat Cell Biol. 2012 Feb 02;14(2):117-23
pubmed: 22298039
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
Nature. 2012 Mar 28;483(7391):603-7
pubmed: 22460905
Blood. 2012 Aug 2;120(5):947-59
pubmed: 22645181
J Struct Biol. 2012 Aug;179(2):104-11
pubmed: 22735043
Mol Cell. 2012 Oct 26;48(2):242-53
pubmed: 22959274
Elife. 2013 Jan 22;2:e00308
pubmed: 23358411
Mol Cell. 2013 Mar 28;49(6):1049-59
pubmed: 23395000
Proc Natl Acad Sci U S A. 2013 Mar 26;110(13):5046-51
pubmed: 23479637
Nature. 2013 Apr 4;496(7443):101-5
pubmed: 23535601
J Cell Sci. 2013 Jul 15;126(Pt 14):3010-20
pubmed: 23687372
Cancer Lett. 2013 Aug 28;337(1):26-34
pubmed: 23726843
Nucleic Acids Res. 2013 Sep;41(16):7683-99
pubmed: 23804767
Nat Chem Biol. 2013 Sep;9(9):548-56
pubmed: 23892893
Neoplasia. 2013 Aug;15(8):989-97
pubmed: 23908598
Elife. 2014;3:e01856
pubmed: 24448410
Nature. 2014 Apr 3;508(7494):108-12
pubmed: 24670634
Biochim Biophys Acta. 2014 Sep;1843(9):1948-68
pubmed: 24732012
Cancer Cell. 2014 May 12;25(5):563-73
pubmed: 24823636
Curr Biol. 2014 Jul 21;24(14):1573-1583
pubmed: 24998528
Proc Natl Acad Sci U S A. 2014 Jul 22;111(29):10586-91
pubmed: 25002487
J Cell Sci. 2014 Sep 15;127(Pt 18):3877-83
pubmed: 25146396
BMC Biol. 2014 Nov 11;12:94
pubmed: 25385277
Am J Physiol Endocrinol Metab. 2015 Feb 15;308(4):E283-93
pubmed: 25491724
Cancer Res. 2015 Feb 1;75(3):544-53
pubmed: 25644265
Sci Signal. 2015 Mar 10;8(367):ra27
pubmed: 25759478
Mol Cell. 2015 Aug 6;59(3):382-98
pubmed: 26190261
Cell Stem Cell. 2015 Nov 5;17(5):585-96
pubmed: 26440282
Genes Dev. 2015 Nov 15;29(22):2331-6
pubmed: 26543160
Cancer Cell. 2015 Nov 9;28(5):653-665
pubmed: 26555175
J Med Chem. 2015 Dec 24;58(24):9480-97
pubmed: 26565666
Cell Death Dis. 2015 Dec 31;6:e2031
pubmed: 26720340
Cell Metab. 2016 Jan 12;23(1):27-47
pubmed: 26771115
Cell Metab. 2016 Mar 8;23(3):517-28
pubmed: 26853747
Nature. 2016 Mar 24;531(7595):523-527
pubmed: 26982722
Elife. 2016 Apr 16;5:
pubmed: 27085088
Nat Cell Biol. 2016 Oct;18(10):1090-101
pubmed: 27617932
Nat Rev Cancer. 2016 Nov;16(11):680-693
pubmed: 27658530
Cell. 2017 Feb 9;168(4):657-669
pubmed: 28187287
Proc Natl Acad Sci U S A. 2017 Apr 4;114(14):3565-3571
pubmed: 28320958
Mol Cancer Ther. 2017 Nov;16(11):2375-2386
pubmed: 28878026
Mol Cell. 2018 Jan 18;69(2):169-181
pubmed: 29107536
Nature. 2017 Dec 14;552(7684):194-199
pubmed: 29211715
Nature. 1988 Mar 31;332(6163):462-4
pubmed: 3352747
JAMA. 1967 Nov 27;202(9):882-8
pubmed: 5234350
Cell. 1995 Sep 22;82(6):905-14
pubmed: 7553851
Mol Cell Biol. 1995 Aug;15(8):4497-506
pubmed: 7623840
Mol Cell Biol. 1996 Aug;16(8):4273-80
pubmed: 8754828
Mol Cell Biol. 1998 Apr;18(4):2282-97
pubmed: 9528799

Auteurs

Katarzyna Parzych (K)

Cancer Cell Protein Metabolism Group, Centre for Haematology, Department of Medicine, Imperial College London, London, UK.

Paula Saavedra-García (P)

Cancer Cell Protein Metabolism Group, Centre for Haematology, Department of Medicine, Imperial College London, London, UK.

Gabriel N Valbuena (GN)

Division of Cancer, Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK.

Hibah A Al-Sadah (HA)

Cancer Cell Protein Metabolism Group, Centre for Haematology, Department of Medicine, Imperial College London, London, UK.

Mark E Robinson (ME)

Centre for Haematology, Department of Medicine, Imperial College London, London, UK.

Lucy Penfold (L)

Cancer Cell Protein Metabolism Group, Centre for Haematology, Department of Medicine, Imperial College London, London, UK.

Desislava M Kuzeva (DM)

Cancer Cell Protein Metabolism Group, Centre for Haematology, Department of Medicine, Imperial College London, London, UK.

Angie Ruiz-Tellez (A)

Cancer Cell Protein Metabolism Group, Centre for Haematology, Department of Medicine, Imperial College London, London, UK.

Sandra Loaiza (S)

Cancer Cell Protein Metabolism Group, Centre for Haematology, Department of Medicine, Imperial College London, London, UK.

Viktoria Holzmann (V)

Cancer Cell Protein Metabolism Group, Centre for Haematology, Department of Medicine, Imperial College London, London, UK.

Valentina Caputo (V)

Centre for Haematology, Department of Medicine, Imperial College London, London, UK.

David C Johnson (DC)

Division of Molecular Pathfology, Institute of Cancer Research, Sutton, UK.

Martin F Kaiser (MF)

Division of Molecular Pathfology, Institute of Cancer Research, Sutton, UK.

Anastasios Karadimitris (A)

Centre for Haematology, Department of Medicine, Imperial College London, London, UK.

Eric W-F Lam (EW)

Division of Cancer, Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK.

Eric Chevet (E)

INSERM U1242, Chemistry, Oncogenesis, Stress, Signaling, Université de Rennes 1, Rennes, France.
Centre de Lutte Contre le Cancer Eugène Marquis Rennes, Rennes, France.

Niklas Feldhahn (N)

Centre for Haematology, Department of Medicine, Imperial College London, London, UK.

Hector C Keun (HC)

Division of Cancer, Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK.

Holger W Auner (HW)

Cancer Cell Protein Metabolism Group, Centre for Haematology, Department of Medicine, Imperial College London, London, UK. holger.auner04@imperial.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH